<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">In this subject situation is far from clear and there are too many unknown factors, which might be operative in the interaction between ACE2, diabetes, ACE inhibitors/ARBs and lung injury. The lack of evidence for either benefit or harm has prompted European Society of Cardiology Council on Hypertension, European Society of Hypertension and American Heart Association to advise continuing with ACE inhibitors and ARBs in case a patient develops COVID-19 [
 <xref ref-type="bibr" rid="CR35">35</xref>]. A clinical trial is underway to study the ARB losartan and recombinant human ACE2 in patients with COVID-19.
</p>
